Thomas C. Kühler

1.2k total citations
27 papers, 991 citations indexed

About

Thomas C. Kühler is a scholar working on Economics and Econometrics, Surgery and Small Animals. According to data from OpenAlex, Thomas C. Kühler has authored 27 papers receiving a total of 991 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 5 papers in Surgery and 5 papers in Small Animals. Recurrent topics in Thomas C. Kühler's work include Pharmaceutical Economics and Policy (7 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Thomas C. Kühler is often cited by papers focused on Pharmaceutical Economics and Policy (7 papers), Helicobacter pylori-related gastroenterology studies (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Thomas C. Kühler collaborates with scholars based in France, Sweden and United Kingdom. Thomas C. Kühler's co-authors include Kerstin Bergman, Anna‐Karin Johansson, Gunnar Alván, Carina Carlsson, Jan-Eric Sjöström, J. Fryklund, Henrik Larsson, Aaron Lee, Håkan Larsson and Norman A. Bergman and has published in prestigious journals such as The Science of The Total Environment, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Thomas C. Kühler

27 papers receiving 958 citations

Peers

Countries citing papers authored by Thomas C. Kühler

Since Specialization

Citations

This map shows the geographic impact of Thomas C. Kühler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas C. Kühler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas C. Kühler more than expected).

Fields of papers citing papers by Thomas C. Kühler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas C. Kühler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas C. Kühler. The network helps show where Thomas C. Kühler may publish in the future.

Co-authorship network of co-authors of Thomas C. Kühler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas C. Kühler. A scholar is included among the top collaborators of Thomas C. Kühler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas C. Kühler. Thomas C. Kühler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM 2024 ·Clinical Therapeutics ·Thomas C. Kühler, (unknown), (unknown), (unknown), (unknown)	1
2	Rolling Reviews During COVID-19: The European Union Experience in a Global Context 2022 ·Clinical Therapeutics ·(unknown), (unknown), (unknown), Thomas C. Kühler	16
3	Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA 2022 ·Clinical Therapeutics ·(unknown), (unknown), Thomas C. Kühler	32
4	Development and Regulation of Connected Combined Products: Reflections From the Medtech & Pharma Platform Association 2022 ·Clinical Therapeutics ·Thomas C. Kühler, (unknown), (unknown), (unknown), (unknown), Ruth A. Foster, Paul Gardner, (unknown), (unknown), (unknown), (unknown), (unknown), Marta M. Swierczynska, (unknown), (unknown)	2
5	Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health—an EFPIA View 2021 ·Clinical Therapeutics ·(unknown), Nasir Hussain, (unknown), (unknown), (unknown), (unknown), Thomas C. Kühler	12
6	Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports? 2021 ·Clinical Therapeutics ·(unknown), (unknown), Neil McAuslane, Lawrence Liberti, Thomas C. Kühler	4
7	The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting 2021 ·Clinical Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Makoto Nagaoka, (unknown), (unknown), Thomas C. Kühler	5
8	Use of Real-world Data for New Drug Applications and Line Extensions 2020 ·Clinical Therapeutics ·(unknown), (unknown), Thomas C. Kühler	64
9	Regulatory Agilities in the Time of COVID-19: Overview, Trends, and Opportunities 2020 ·Clinical Therapeutics ·(unknown), (unknown), (unknown), (unknown), Makoto Nagaoka, (unknown), (unknown), Wei Yu, Thomas C. Kühler	30
10	To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016 2019 ·BMJ Open ·Thomas C. Kühler, (unknown), Neil McAuslane, Lawrence Liberti	8
11	Orphan Medicines for Pediatric Use: A Focus on the European Union 2019 ·Clinical Therapeutics ·(unknown), Solange Corriol‐Rohou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Thomas C. Kühler	9
12	From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety 2019 ·Therapeutic Innovation & Regulatory Science ·(unknown), (unknown), (unknown), (unknown), Thomas C. Kühler	10
13	Do Biological Medicinal Products Pose a Risk to the Environment? 2009 ·Drug Safety ·Thomas C. Kühler, Mikael Andersson, Gunnar Carlin, Ann Johnsson, (unknown)	6
14	Are pharmaceuticals potent environmental pollutants? 2005 ·The Science of The Total Environment ·Carina Carlsson, Anna‐Karin Johansson, Gunnar Alván, Kerstin Bergman, Thomas C. Kühler	345
15	Are pharmaceuticals potent environmental pollutants? 2005 ·The Science of The Total Environment ·Carina Carlsson, Anna‐Karin Johansson, Gunnar Alván, Kerstin Bergman, Thomas C. Kühler	59
16	Chemical information management in drug discovery: optimizing the computational and combinatorial chemistry interfaces 2000 ·Journal of Molecular Graphics and Modelling ·Tudor I. Oprea, Johan Gottfries, (unknown), Peder Svensson, Thomas C. Kühler	42
17	Chemical information management in drug discovery: Optimizing the computational and combinatorial chemistry interfaces 2000 ·Journal of Molecular Graphics and Modelling ·Tudor I. Oprea, Johan Gottfries, (unknown), Peder Svensson, Thomas C. Kühler	7
18	In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions 1996 ·Antimicrobial Agents and Chemotherapy ·Jan-Eric Sjöström, J. Fryklund, Thomas C. Kühler, Henrik Larsson	30
19	Structure-Activity Relationship of Omeprazole and Analogs as Helicobacter pylori Urease Inhibitors 1995 ·Journal of Medicinal Chemistry ·Thomas C. Kühler, J. Fryklund, Norman A. Bergman, (unknown), Aaron Lee, Håkan Larsson	82
20	Mercapturic acid metabolites from 2-, 3-, and 4-ethenyl-methylbenzenes in the rat 1984 ·Xenobiotica ·Thomas C. Kühler	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact